Clinical Trial Update: Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

This update reports the Phase 3 results for the oral agent BG00012 in relapsing-remitting multiple sclerosis, focusing on efficacy and safety. The trial is comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2014-06-02